Results 41 to 50 of about 982 (100)

Assessment of Early Cardiotoxicity and Cardiac Dysfunction of Radioligand Therapy in Patients with Neuroendocrine Tumors. [PDF]

Cancers (Basel)
Jóźwik-Plebanek K, Saracyn M, Kołodziej M, Mądra W, Durma AD, Dziuk M, Balcerska Z, Janiak K, Gniadek-Olejniczak K, Kamiński G.   +9 more
europepmc   +1 more source

Multifactorial analysis of radiochemical purity in high-activity ¹⁷⁷Lu-labeled theranostics: impact of precursor source, ¹⁷⁷Lu form, and production parameters. [PDF]

EJNMMI Radiopharm Chem
Hunt W, Long M, Kamil U, Kellapatha S, Noonan W, Roselt PD, Papa N, Emmerson B, Hofman MS, Haskali MB.   +9 more
europepmc   +1 more source

Shift in secretory profile of a pNET: from indolent glucagonoma to aggressive insulinoma - a case report. [PDF]

Front Endocrinol (Lausanne)
Gil Dos Santos S, Calheiros R, Oliveira J, Santos AP, Souteiro P.   +4 more
europepmc   +1 more source

Predictors of renal function decline in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy. [PDF]

EJNMMI Res
Herr FL, Dascalescu C, Fusch V, Smith C, Ebner R, Zacherl MJ, Eckenweber F, Klimek K, Auernhammer CJ, Spitzweg C, Ricke J, Heimer MM, Cyran CC, Werner RA, Sheikh GT.   +14 more
europepmc   +1 more source

PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). [PDF]

Endocr Relat Cancer
Corbett V, Gupta G, Chauhan A.
europepmc   +1 more source

The impact of radioligand therapy on prognosis in patients with lung neuroendocrine tumors. [PDF]

Front Endocrinol (Lausanne)
Jóźwik-Plebanek K, Saracyn M, Durma AD, Kołodziej M, Mądra W, Dziuk M, Janiak K, Balcerska Z, Gniadek-Olejniczak K, Kamiński G.   +9 more
europepmc   +1 more source

<i>CopperNostics</i>-Here We Are Now, Entertain Us! [PDF]

Pharmaceuticals (Basel)
Brühlmann SA, Walther M, Kopka K, Kreller M, Kiss OC.   +4 more
europepmc   +1 more source

Challenges and Opportunities in Radioligand Therapy. [PDF]

J Nucl Med Technol
Currie GM, Bailey DL.
europepmc   +1 more source

Correction to: Safety and dosimetry of [¹⁷⁷Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study. [PDF]

Eur J Nucl Med Mol Imaging
Gaze MN, Handkiewicz-Junak D, Hladun R, Laetsch TW, Sorge C, Sparks R, Wan S, Ceraulo A, Kluczewska-Galka A, Gámez-Cenzano C, States LJ, El Khouli R, Aimone P, Perraud K, Kollar G, Khanshan F, Blumenstein L, Brouri F, Giraudet AL.   +18 more
europepmc   +1 more source

Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells. [PDF]

Theranostics
Nguyen N, Min Y, Rivière J, van der Garde M, Ghosh S, Bartos LM, Brendel M, Bassermann F, Azhdarinia A, Weber WA, Götze KS, Kossatz S.   +11 more
europepmc   +1 more source